Here is the design of a clinical trial:

Official Title: Effectiveness of High-frequency rTMS in Reducing Alcohol Consumption in Non-abstinent Patients With an Alcohol Use Disorder: A Multicentre Randomised Controlled Study

Included conditions:
- Alcoholism
- rTMS Stimulation

Study Armgroups:
- {'label': 'test group', 'type': 'EXPERIMENTAL', 'interventionNames': ['Device: Active rTMS', 'Other: Questionnaires', 'Device: Breathalyzer']}
- {'label': 'control group', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Device: Placebo rTMS', 'Other: Questionnaires', 'Device: Breathalyzer']}

Interventions:
- {'type': 'DEVICE', 'name': 'Active rTMS', 'description': 'Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.\n\nA total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC', 'armGroupLabels': ['test group']}
- {'type': 'DEVICE', 'name': 'Placebo rTMS', 'description': 'Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.\n\nA total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation.', 'armGroupLabels': ['control group']}
- {'type': 'OTHER', 'name': 'Questionnaires', 'description': 'questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA', 'armGroupLabels': ['control group', 'test group']}
- {'type': 'DEVICE', 'name': 'Breathalyzer', 'description': 'estimation of blood alcohol level', 'armGroupLabels': ['control group', 'test group']}

Primary Outcomes:
- {'measure': 'total alcohol consumption (g/d)', 'description': 'total alcohol consumption (g/d), measured by average daily consumption', 'timeFrame': 'through study completion, an average of 1 month'}
- {'measure': 'number of days of high consumption', 'description': 'reduction in the number of days of high consumption (≥ 60 g/d for men, ≥ 40 g/d for women)', 'timeFrame': 'through study completion, an average of 1 month'}

Please estimate the sample size based on the assumption: 
Significance level of 1.25% (co-primary outcome), power of 80%, and a 20% rate of premature withdrawal or non-initiation of treatment.
Sample size calculation
        The sample size was calculated using PASS software (version 11, Kayesville, UT, USA) [27]. As the primary efficacy outcome, the EMA recommend using both TAC and the number of HDD [1]. Besides, any reduction in total alcohol consumption of at least 10âg/day for patients with alcohol use disorders will reduce the annual and lifetime risk of alcohol-related death [28].
        In this context, the sample size calculation based on an expected difference between the treatment groups of 15âg/day in total alcohol consumption or 3âdays per month, with a standard deviation for the TAC of 30âg/day and with an autocorrelation of 0.3 to 0.7 between observations in the same subject, between 82 and 122 patients, would be required.
        Considering a significance level of 1.25% (co-primary outcome) and a power of 80%, and with the hypothesis of a premature withdrawal or a non-initiation of treatment (acute repeated alcoholism) for 20% of individuals, 144 patients (72 per group) should be included to meet the objectives of the study.